Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Effect of Environment on the Evolutionary Trajectories and Growth Characteristics of Antibiotic-Resistant Escherichia coli Mutants.

Hubbard ATM, Jafari NV, Feasey N, Rohn JL, Roberts AP.

Front Microbiol. 2019 Aug 28;10:2001. doi: 10.3389/fmicb.2019.02001. eCollection 2019.

2.

The UK cellular microbiology network: Exploring the host-bacterial interface.

Rohn JL, Mostowy S, King JS, Unnikrishnan M, Gutierrez MG.

Cell Microbiol. 2019 Sep;21(9):e13081. doi: 10.1111/cmi.13081. Epub 2019 Jul 17.

3.

Ultrasound-activated microbubbles as a novel intracellular drug delivery system for urinary tract infection.

Horsley H, Owen J, Browning R, Carugo D, Malone-Lee J, Stride E, Rohn JL.

J Control Release. 2019 May 10;301:166-175. doi: 10.1016/j.jconrel.2019.03.017. Epub 2019 Mar 20.

4.

Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis.

Swamy S, Kupelian AS, Khasriya R, Dharmasena D, Toteva H, Dehpour T, Collins L, Rohn JL, Malone-Lee J.

Int Urogynecol J. 2019 Mar;30(3):409-414. doi: 10.1007/s00192-018-3846-5. Epub 2018 Dec 18.

5.

Reassessment of Routine Midstream Culture in Diagnosis of Urinary Tract Infection.

Sathiananthamoorthy S, Malone-Lee J, Gill K, Tymon A, Nguyen TK, Gurung S, Collins L, Kupelian AS, Swamy S, Khasriya R, Spratt DA, Rohn JL.

J Clin Microbiol. 2019 Feb 27;57(3). pii: e01452-18. doi: 10.1128/JCM.01452-18. Print 2019 Mar.

6.

Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: What should we do?

Swamy S, Barcella W, De Iorio M, Gill K, Khasriya R, Kupelian AS, Rohn JL, Malone-Lee J.

Int Urogynecol J. 2018 Jul;29(7):1035-1043. doi: 10.1007/s00192-018-3569-7. Epub 2018 Mar 20.

7.

A urine-dependent human urothelial organoid offers a potential alternative to rodent models of infection.

Horsley H, Dharmasena D, Malone-Lee J, Rohn JL.

Sci Rep. 2018 Jan 19;8(1):1238. doi: 10.1038/s41598-018-19690-7.

8.

Evolution of Communities in the Medical Sciences: Evidence from the Medical Words Network.

Shirazi AH, Badie Modiri A, Heydari S, Rohn JL, Jafari GR, Mani AR.

PLoS One. 2016 Dec 2;11(12):e0167546. doi: 10.1371/journal.pone.0167546. eCollection 2016.

9.

Physio-chemical and antibacterial characteristics of pressure spun nylon nanofibres embedded with functional silver nanoparticles.

Xu Z, Mahalingam S, Rohn JL, Ren G, Edirisinghe M.

Mater Sci Eng C Mater Biol Appl. 2015 Nov 1;56:195-204. doi: 10.1016/j.msec.2015.06.003. Epub 2015 Jun 9.

10.

Urinary ATP as an indicator of infection and inflammation of the urinary tract in patients with lower urinary tract symptoms.

Gill K, Horsley H, Kupelian AS, Baio G, De Iorio M, Sathiananamoorthy S, Khasriya R, Rohn JL, Wildman SS, Malone-Lee J.

BMC Urol. 2015 Feb 21;15:7. doi: 10.1186/s12894-015-0001-1.

11.

Myo19 ensures symmetric partitioning of mitochondria and coupling of mitochondrial segregation to cell division.

Rohn JL, Patel JV, Neumann B, Bulkescher J, Mchedlishvili N, McMullan RC, Quintero OA, Ellenberg J, Baum B.

Curr Biol. 2014 Nov 3;24(21):2598-605. doi: 10.1016/j.cub.2014.09.045. Epub 2014 Oct 23.

12.

Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection.

Horsley H, Malone-Lee J, Holland D, Tuz M, Hibbert A, Kelsey M, Kupelian A, Rohn JL.

PLoS One. 2013 Dec 10;8(12):e83637. doi: 10.1371/journal.pone.0083637. eCollection 2013.

13.

An encapsulated drug delivery system for recalcitrant urinary tract infection.

Labbaf S, Horsley H, Chang MW, Stride E, Malone-Lee J, Edirisinghe M, Rohn JL.

J R Soc Interface. 2013 Sep 25;10(89):20130747. doi: 10.1098/rsif.2013.0747. Print 2013 Dec 6.

14.

Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms.

Khasriya R, Sathiananthamoorthy S, Ismail S, Kelsey M, Wilson M, Rohn JL, Malone-Lee J.

J Clin Microbiol. 2013 Jul;51(7):2054-62. doi: 10.1128/JCM.03314-12. Epub 2013 Apr 17.

15.

Discrediting microscopic pyuria and leucocyte esterase as diagnostic surrogates for infection in patients with lower urinary tract symptoms: results from a clinical and laboratory evaluation.

Kupelian AS, Horsley H, Khasriya R, Amussah RT, Badiani R, Courtney AM, Chandhyoke NS, Riaz U, Savlani K, Moledina M, Montes S, O'Connor D, Visavadia R, Kelsey M, Rohn JL, Malone-Lee J.

BJU Int. 2013 Jul;112(2):231-8. doi: 10.1111/j.1464-410X.2012.11694.x. Epub 2013 Jan 10.

16.

Changes in Ect2 localization couple actomyosin-dependent cell shape changes to mitotic progression.

Matthews HK, Delabre U, Rohn JL, Guck J, Kunda P, Baum B.

Dev Cell. 2012 Aug 14;23(2):371-83. doi: 10.1016/j.devcel.2012.06.003.

17.

FMNL2 drives actin-based protrusion and migration downstream of Cdc42.

Block J, Breitsprecher D, Kühn S, Winterhoff M, Kage F, Geffers R, Duwe P, Rohn JL, Baum B, Brakebusch C, Geyer M, Stradal TE, Faix J, Rottner K.

Curr Biol. 2012 Jun 5;22(11):1005-12. doi: 10.1016/j.cub.2012.03.064. Epub 2012 May 17.

18.

Differential regulation of actin microfilaments by human MICAL proteins.

Giridharan SS, Rohn JL, Naslavsky N, Caplan S.

J Cell Sci. 2012 Feb 1;125(Pt 3):614-24. doi: 10.1242/jcs.089367. Epub 2012 Feb 13.

19.

Comparative RNAi screening identifies a conserved core metazoan actinome by phenotype.

Rohn JL, Sims D, Liu T, Fedorova M, Schöck F, Dopie J, Vartiainen MK, Kiger AA, Perrimon N, Baum B.

J Cell Biol. 2011 Sep 5;194(5):789-805. doi: 10.1083/jcb.201103168.

20.

Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration.

Bai SW, Herrera-Abreu MT, Rohn JL, Racine V, Tajadura V, Suryavanshi N, Bechtel S, Wiemann S, Baum B, Ridley AJ.

BMC Biol. 2011 Aug 11;9:54. doi: 10.1186/1741-7007-9-54.

21.

Tao-1 is a negative regulator of microtubule plus-end growth.

Liu T, Rohn JL, Picone R, Kunda P, Baum B.

J Cell Sci. 2010 Aug 15;123(Pt 16):2708-16. doi: 10.1242/jcs.068726. Epub 2010 Jul 20.

22.

Actin and cellular architecture at a glance.

Rohn JL, Baum B.

J Cell Sci. 2010 Jan 15;123(Pt 2):155-8. doi: 10.1242/jcs.049759. No abstract available.

23.

Cell shape: taking the heat.

Kunda P, Rohn JL, Baum B.

Curr Biol. 2008 Jun 3;18(11):R470-2. doi: 10.1016/j.cub.2008.04.032.

24.

Relevance of apoptin's integrity for its functional behavior.

Rohn JL, Zhang YH, Leliveld SR, Danen-van Oorschot AA, Henriquez NV, Abrahams JP, Noteborn MH.

J Virol. 2005 Jan;79(2):1337-8. No abstract available.

25.
26.

Gene targeting: attention to detail.

Vanhaesebroeck B, Rohn JL, Waterfield MD.

Cell. 2004 Aug 6;118(3):274-6.

27.

The viral death effector Apoptin reveals tumor-specific processes.

Rohn JL, Noteborn MH.

Apoptosis. 2004 May;9(3):315-22. Review.

PMID:
15258463
28.

Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing.

Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, Boesen-de Cock JG, Rohn JL, Borst J, Noteborn MH.

Cell Death Differ. 2004 May;11(5):564-73.

29.

Apoptin's functional N- and C-termini independently bind DNA.

Leliveld SR, Dame RT, Rohn JL, Noteborn MH, Abrahams JP.

FEBS Lett. 2004 Jan 16;557(1-3):155-8.

30.

Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion.

Zhang YH, Leliveld SR, Kooistra K, Molenaar C, Rohn JL, Tanke HJ, Abrahams JP, Noteborn MH.

Exp Cell Res. 2003 Sep 10;289(1):36-46.

PMID:
12941602
31.

Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA.

Leliveld SR, Dame RT, Mommaas MA, Koerten HK, Wyman C, Danen-van Oorschot AA, Rohn JL, Noteborn MH, Abrahams JP.

Nucleic Acids Res. 2003 Aug 15;31(16):4805-13.

32.

Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Rutjes SA, Bosma PJ, Rohn JL, Noteborn MH, Wesseling JG.

J Mol Med (Berl). 2003 Sep;81(9):558-65. Epub 2003 Jul 16.

PMID:
12879152
33.

Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis.

Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH.

J Biol Chem. 2003 Jul 25;278(30):27729-36. Epub 2003 May 16.

34.

Apoptin induces tumor-specific apoptosis as a globular multimer.

Leliveld SR, Zhang YH, Rohn JL, Noteborn MH, Abrahams JP.

J Biol Chem. 2003 Mar 14;278(11):9042-51. Epub 2002 Dec 19.

35.

A tumor-specific kinase activity regulates the viral death protein Apoptin.

Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, Van De Velde CJ, Kuppen PJ, Mumberg D, Donner P, Noteborn MH.

J Biol Chem. 2002 Dec 27;277(52):50820-7. Epub 2002 Oct 21.

36.

Akt mediates insulin rescue from apoptosis in brown adipocytes: effect of ceramide.

Navarro P, Valverde AM, Rohn JL, Benito M, Lorenzo M.

Growth Horm IGF Res. 2000 Oct;10(5):256-66.

PMID:
11042022
37.
38.

Lymphokines modulate the growth and survival of thymic tumor cells containing a novel feline leukemia virus/Notch2 variant.

Linenberger ML, Rohn JL, Deng T, Ellis-Smith S, Ingber R, Overbaugh J.

Vet Immunol Immunopathol. 1999 Sep 20;70(3-4):223-43.

PMID:
10507363
39.

The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis.

Rohn JL, Hueber AO, McCarthy NJ, Lyon D, Navarro P, Burgering BM, Evan GI.

Oncogene. 1998 Dec 3;17(22):2811-8.

40.

In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.

Rohn JL, Moser MS, Gwynn SR, Baldwin DN, Overbaugh J.

J Virol. 1998 Apr;72(4):2686-96.

41.

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model.

Rohn JL, Gwynn SR, Lauring AS, Linenberger ML, Overbaugh J.

Leukemia. 1996 Dec;10(12):1867-9. Review.

PMID:
8946923
42.

Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.

Rohn JL, Lauring AS, Linenberger ML, Overbaugh J.

J Virol. 1996 Nov;70(11):8071-80.

43.
44.

Supplemental Content

Support Center